Equities

Principal Technologies Inc

Principal Technologies Inc

Actions
  • Price (CAD)0.150
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change+50.00%
  • Beta--
Data delayed at least 15 minutes, as of Jun 07 2024.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Principal Technologies Inc. is a Canada-based company. The Company is engaged in building a diverse portfolio of investments in healthcare technology companies with a focus on those with global distribution potential which have intellectual property capable of enhancing medical treatment quality, cost efficiency, optimization of the patient pathway, and implementation of point of care technologies. It operates in one operational segment, being its operations in healthcare technology, including the project management of international scale clinical studies primarily related to medical device technologies. The Company's subsidiaries include Principal Technologies Capital Management GmbH and E&E CRO Consulting GmbH.

  • Revenue in CAD (TTM)581.16k
  • Net income in CAD-1.52m
  • Incorporated2018
  • Employees--
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
PTEC:CVE since
announced
Transaction
value
VIVOSTAT A/SAnnounced06 Feb 202406 Feb 2024Announced0.00%8.43m
Data delayed at least 15 minutes, as of Jun 07 2024.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Delta 9 Cannabis Inc70.65m-19.60m4.44m200.00------0.0629-0.1022-0.10220.3695-0.03930.89623.2133.79353,264.40-23.37-13.74-73.68-23.3926.0626.99-26.08-17.980.0875-4.291.18--12.3956.5035.61---48.22--
Innovotech Inc1.24m-176.78k4.49m16.00--5.41--3.61-0.0045-0.00450.03190.02131.136.107.97---16.102.90-19.153.5669.6371.56-14.252.192.24--0.00--5.057.42-15.43--35.69--
Entourage Health Corp41.58m-42.94m4.60m251.00------0.1107-0.1394-0.13940.135-0.49790.97632.6412.84---100.84-55.14---150.9216.59-40.59-103.28-199.990.0778-0.616911.61---0.43838.6262.51---49.49--
Hemostemix Inc0.00-1.70m4.79m-----------0.0189-0.01890.00-0.090.00-------571.80-599.98---------------2.45--------52.21------
StageZero Life Sciences Ltd-100.00bn-100.00bn4.92m40.00---------------0.113-----------135.76-------2.74---246.920.0176-------25.1255.93-52.53------
Principal Technologies Inc581.16k-1.52m4.93m----6.07--8.48-0.0657-0.06570.02570.02470.577--3.71---147.50---286.94--42.98---255.65-----59.800.0757--25.43--23.53------
Appili Therapeutics Inc1.15m-5.34m5.46m8.00------4.75-0.044-0.0440.0095-0.08110.5047--2.12---234.31-117.41---173.66-----464.23-3,037.15---5.32-----75.97--63.20---43.04--
Data as of Jun 07 2024. Currency figures normalised to Principal Technologies Inc's reporting currency: Canadian Dollar CAD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.